|Bid||3.3300 x 800|
|Ask||3.4000 x 800|
|Day's Range||3.0701 - 3.4700|
|52 Week Range||3.0300 - 10.8100|
|Beta (5Y Monthly)||1.40|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 16, 2022 - Feb 21, 2022|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||N/A|
By David Bautz, PhD NASDAQ:MNOV READ THE FULL MNOV RESEARCH REPORT Business Update MN-166 in Combination with PD-1 Inhibitor Extends Survival in Preclinical Model On November 22, 2021, MediciNova, Inc. (NASDAQ:MNOV) announced results from a preclinical study of MN-166 (ibudilast) in combination with a PD-1 inhibitor presented at the 26 th Annual Meeting of the Society for Neuro-Oncology (SNO).
LA JOLLA, Calif., Nov. 22, 2021 (GLOBE NEWSWIRE) -- MediciNova, Inc., a biopharmaceutical company traded on the NASDAQ Global Market (NASDAQ:MNOV) and the JASDAQ Market of the Tokyo Stock Exchange (Code Number: 4875), today announced that MediciNova’s research collaborator, Justin Lathia PhD, Co-Director of the Brain Tumor Research and Therapeutic Development Center of Excellence at Cleveland Clinic Lerner Research Institute, and Professor, Department of Molecular Medicine at Cleveland Clinic Le
There's no doubt that money can be made by owning shares of unprofitable businesses. For example, biotech and mining...